Social Isolation Clinical Trial
Official title:
Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept Physiopathological Study (CRH Study)
Verified date | March 2022 |
Source | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, corticorelin hormone (CRH) has shown to increase OT release. This study is designed to evaluate oxytocin values after administration of CRH in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following CRH in patients with hypopituitarism compared to healthy controls.
Status | Completed |
Enrollment | 52 |
Est. completion date | May 1, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Patients with hypopituitarism (HYPO) (>1 pituitary hormone deficiency) and stable hormone replacement for the prior three months - At least one clinical sign of hypothalamic damage - Female participants will be done in the early to midfollicular phase Exclusion Criteria: - uncorrected hormone deficiency - creatinine >1.5mg/dL - alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5x upper limit of normal - hematocrit less than 30% - suicidality or active psychosis - participation in a trial with investigational drugs within 30 days - using a high glucocorticoid dose - vigorous physical exercise - alcohol intake within 24 hours before the study participation - evidence of any acute illness or any illness that the Investigator determines could interfere with study participation or safety - pregnancy or breastfeeding for last 8 weeks - known allergies towards CRH - patients refusing or unable to give written informed consent - Additionally for healthy controls: the presence of brain or pituitary tumor, radiation involving the hypothalamus or pituitary, history of hypopituitarism or receiving testosterone or glucocorticoids esters. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Instituto de Salud Carlos III |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in oxytocin concentration | Change in oxytocin concentration (pg/mL) after administration of 1.0 µg/kg/body weight of CRH or 0.9% sodium chloride (NaCl) | Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection | |
Secondary | Maximal change in oxytocin concentration (pg/mL) | Maximal change in oxytocin concentration (pg/mL) after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl | Within the two hours after the injection | |
Secondary | Overall oxytocin secretion | Oxytocin area under the curve after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl | Within the two hours after the injection | |
Secondary | Change in cortisol concentration (nmol/L) | Change in cortisol concentration (nmol/L) after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl | Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection | |
Secondary | Change in adrenocorticotropic hormone (ACTH) values | Change in ACTH values (pmol/L) after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl | Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection | |
Secondary | Mood assessment | Correlation between Beck Depression Inventory-2 score (range from 0 to 63, higher scores mean a worse outcome) and baseline oxytocin concentration (pg/mL) | Baseline | |
Secondary | Quality of life assessment | Correlation between 36 item- Short Form Health Survey score (range from 0 to 100, the higher scores indicate better health status) and baseline oxytocin concentration (pg/mL) | Baseline | |
Secondary | Impulsivity assessment | Correlation between Barratt Impulsiveness Scale (range from 30 to 120, higher scores indicate greater impulsivity) and baseline oxytocin concentration (pg/mL) | Baseline | |
Secondary | Alexithymia assessment | Correlation between Toronto Alexithymia scales-20 score (range from 20 to 100, higher scores mean a worse outcome) and baseline oxytocin concentration (pg/mL) | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05831475 -
LEAPTogether: An Intergenerational Intervention to Address Loneliness and Social Isolation
|
N/A | |
Completed |
NCT03291717 -
Bridging Community Gaps Photovoice
|
N/A | |
Recruiting |
NCT06175299 -
Social Functions to Promote Home-based Cognitive Training
|
N/A | |
Completed |
NCT04573972 -
Using Social Connectedness to Increase Physical Activity
|
N/A | |
Not yet recruiting |
NCT05031247 -
Refugee Mental Health and Wellness Pilot Study
|
N/A | |
Completed |
NCT02596672 -
Promoting Walking in Older Adults Living in Independent Living Communities in Northern Ireland: A Feasibility Study.
|
N/A | |
Active, not recruiting |
NCT05678985 -
Evaluating Impact and Implementation of Choose to Move (Phase 4)
|
N/A | |
Active, not recruiting |
NCT04072185 -
PHYSICAL ACTIVITY AS A MEASURE OF IMPROVING THE EMOTIONAL STATE AND SOCIALIZATION IN THE ELDERLY
|
N/A | |
Completed |
NCT06018974 -
Digital Gaming Intervention for Older People in Long-term Care
|
N/A | |
Recruiting |
NCT04897802 -
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
|
Phase 4 | |
Recruiting |
NCT06138301 -
Telepsychiatry for Social Isolation in Youths
|
N/A | |
Enrolling by invitation |
NCT06434298 -
Provincial Scale-up of Choose to Move (CTM) Phase 4
|
N/A | |
Recruiting |
NCT05520450 -
Telematic Support Group in Patients With Feelings of Loneliness and Social Isolation
|
||
Recruiting |
NCT05019053 -
Acceptability/Feasibility of COVID-19 Intervention
|
N/A | |
Completed |
NCT04567940 -
ENRED@TE. Social Support in Southern Spain. Interventional Study
|
N/A | |
Completed |
NCT04281654 -
Effects of Arts Engagement on Physical Performance, Cognition, Social Isolation, and Self-Perception in Older Adults
|
N/A | |
Completed |
NCT03472729 -
AGE-ON 2.0: Expanding and Evaluating a Tablet Training Program for Older Adults
|
N/A | |
Completed |
NCT03293823 -
HARP-Project 1 Cognitive Training
|
N/A | |
Completed |
NCT02835989 -
Community Paramedicine at Home
|
N/A | |
Completed |
NCT02041585 -
Discharge Functional Status and Rehospitalization in the Elderly
|